Keynote on U.S. Health Reform at Global E-Health Forum - Hamburg 2010

25-26 October 2010, Hamburg, Germany.
Harry Reynolds, Chair of the National Committee on Vital and Health Statistics (NCVHS) and Chair of Council for Affordable Quality Healthcare (CAQH) CORE Initiative, will deliver the keynote speech at the Global E-Health Forum. Title of his presentation is "U.S. Health Reform: Significant Change, Varied Reaction, Opportunities Abound, and Outcome Uncertain".

The first conference day at the Hamburg Chamber of Commerce will also feature presentations of speakers from New Zealand, Europe and South Korea. During breakout sessions, participants have the opportunity to attend various workshops and discussion forums. The accompanying exhibition presents products and service of solution providers. An evening reception in the U.S. Consulate General ("the little White House at the lake Alster") will conclude the day.

The second day will take place at Asklepios clinics. There, the hosts of the Global E-Health Forum - European Health Telematics Association (EHTEL), Hamburg Chamber of Commerce and IBM - have organized, in cooperation with Asklepios, guided tours, best practice presentations and a panel discussion.

If you are interested in the sponsorship opportunities or in exhibiting at the Global E-Health Forum on October 25 in the Hamburg Chamber of Commerce, please explore:

For further information and registration, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...